PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026American Heart Journal5 citationsOpen Access

Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial Fibrillation: Rationale and Design of the CATALYST Trial

View Full Paper
VRVivek Y. ReddyEHElaine HylekACA. John Camm

Key Points

  • Left atrial appendage occlusion may provide advantages over NOACs for managing atrial fibrillation.
  • The CATALYST trial is designed to evaluate this comparison in clinical settings.
  • Participants will be monitored for effectiveness and safety across various treatment groups.
  • The findings could lead to better treatment strategies in atrial fibrillation patients.

Abstract

URL https://clinicaltrials.gov; Unique Identifier NCT04226547.

Expert Takes1 quote

“From a clinical perspective, CLOSURE-AF reinforces the importance of careful patient selection for LAAO and highlights the continued central role of DOAC therapy in eligible patients. Trials such as the recently published CHAMPION-AF (Watchman Flx versus NOAC for Embolic Protection in the Managem...”

ACC Journal ScanView source
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Reddy et al. (2026) studied this question.

synapsesocial.com/papers/69a76555badf0bb9e87d8be7https://doi.org/10.1016/j.ahj.2026.107367
Ask AI
Helpful
Bookmark
Share
View Full Paper